Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 1, 2001, Pages 290-296

  Kang, Jiesheng ^a   Chen, Xiao Liang ^a   Wang, Lin ^a   Rampe, David ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; HALOFANTRINE; MEFLOQUINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; QUINIDINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG STRUCTURE; ELECTROPHYSIOLOGY; HEART; HEART REPOLARIZATION; HUMAN; IC 50; NONHUMAN; PATCH CLAMP; PHARMACOLOGICAL BLOCKING; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL;

ANIMALS; ANTIMALARIALS; CATION TRANSPORT PROTEINS; CHO CELLS; CRICETINAE; DNA-BINDING PROTEINS; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; KCNQ POTASSIUM CHANNELS; KCNQ1 POTASSIUM CHANNEL; MEFLOQUINE; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; QUINIDINE; TRANS-ACTIVATORS;

EID: 0034812621     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
2. Suppression of time-dependent outward current in guinea pig ventricular myocytes: Actions of quinidine and amiodarone
3. Ks cardiac potassium current
4. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers
5. + current on repolarization in human and guinea pig ventricular myocytes
6. Ks
7. ECG pharmacodynamics and pharmacokinetics of halofantrine and mefloquine
8. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
9. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: A double-blind, placebo-controlled trial
10. Mefloquine and ototoxicity: A report of 3 cases
11. Improved patch clamp techniques for high resolution current recording from cells and cell free membrane patches
12. Clinical features and management of poisoning due to antimalarial drugs
13. + channel by the neuroleptic pimozide
14. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males
15. Clinical pharmacokinetics of mefloquine
16. c and action potential duration
17. Potentiation of halofantrine-induced QTc prolongation by mefloquine: Correlation with blood concentrations of halofantrine
18. Drug overdoses with antimalarial agents: Prescribing and dispensing errors
19. Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I-Ks, in canine models of malignant ischemic ventricular arrhythmia
20. Blockade of HERG potassium channels by the antimalarial halofantrine
21. + channel by the gastrointestinal prokinetic agent cisapride
22. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome
23. Cardiac effects of antimalarial treatment with halofantrine
24. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy
25. Modulation of HERG potassium channels by extracellular magnesium and quinidine
26. Genetic and molecular basis for cardiac arrhythmias: Impact on clinical management parts I and II
27. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG
28. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG
29. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine
30. Ks potassium channel
31. Kr potassium channel
32. Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels
33. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastmizole